Document:

ctmx-ex105_179.htm

Confidential Treatment Requested by CytomX Therapeutics, Inc.

 

Exhibit 10.5

 

SECOND AMENDMENT TO RESEARCH COLLABORATION AGREEMENT

This Second Amendment to Research Collaboration Agreement (the “Second Amendment”) is made effective as of the date of the last signature below by and between ImmunoGen, Inc., a Massachusetts corporation (“ImmunoGen”), with its principal place of business being 830 Winter Street, Waltham, Massachusetts 02451, USA, and CytomX Therapeutics, Inc., a Delaware corporation (“CytomX”), with its principal place of business being 343 Oyster Point Blvd., Suite 100, South San Francisco, California 94080. ImmunoGen and CytomX are herein sometimes referred to as a “Party” and collectively as the “Parties.”

WHEREAS, ImmunoGen and CytomX are parties to that certain Research Collaboration Agreement dated as of January 8, 2014, as amended effective April 3, 2015 (the “RCA”); and 

WHEREAS, the Parties desire to amend the RCA to provide CytomX with the ability to evaluate a second Replacement Target following its first exercise of the CytomX Option, as set forth in this Second Amendment; and 

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree and covenant as follows.

1.Target Replacement Right. Section 2.1.2 of the RCA is deleted in its entirety and replaced with the following:

“2.1.2 Target Replacement Right. Each Party shall have the right to replace each of its initial Research Program Targets with another single Target (a “Replacement Target”), exercisable upon written notice to the other Party, at any time on or prior to the three (3)-year anniversary of the Effective Date (the “Replacement Target Cut-Off Date”), provided that neither Party may replace an initial Research Program Target with a Replacement Target once the Party has exercised its Option with respect to such initial Research Program Target. For clarity, even though CytomX’s Research Program Target set forth on Exhibit A consists of two (2) potential Targets due to cross-reactivity, the Probody used to make the Agreement PDC that Targets CytomX’s Replacement Target shall not be a bi-specific Probody or otherwise cross-react with any Target other than the single Replacement Target. A Replacement Target may not be a Target that is or was previously a Research Program Target of the other Party. Anything contained in this Agreement to the contrary notwithstanding, CytomX shall have the right to replace its first Replacement Target with another single Replacement Target, exercisable upon written notice to ImmunoGen and payment to ImmunoGen of a fee in the amount of [***] U.S. Dollars ($[***]) (the “Expanded Access Fee”) at any time after CytomX has replaced its initial Research Program Targets with a Replacement Target but on or prior to the Replacement Target Cut-Off Date. Any such second Replacement Target for CytomX may not be a Target that is or was previously a Research Program Target of ImmunoGen, and availability of any such second Replacement Target shall be subject to Section 2.1.3 hereof. Payment of the Expanded 

[***] Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by CytomX Therapeutics, Inc.

 

Access Fee by CytomX to ImmunoGen shall be made in U.S. Dollars without set-off or counterclaim and free and clear of any taxes, duties, levies, fees or charges. The Expansion Fee shall be non-refundable and non-creditable. [***]

2.Miscellaneous. Capitalized terms used and not otherwise defined herein shall have the respective meanings ascribed to them in the RCA. The RCA remains in full force and effect, as amended by this Second Amendment. References in the RCA to “Agreement’’ mean the RCA as amended by this Second Amendment.

[The remainder of this page has been intentionally left blank The signature page follows.]

2

[***] Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by CytomX Therapeutics, Inc.

 

IN WITNESS WHEREOF, the Parties have caused this Second Amendment to Research Collaboration Agreement to be executed by their duly authorized representatives.

 

							
	
IMMUNOGEN, INC.
	
 
	
CYTOMX THERAPEUTICS, INC.

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
By:
	
 
	
/s/ Peter Williams
	
 
	
By:
	
 
	
/s/ Debanjan Ray

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Name:
	
 
	
Peter Williams
	
 
	
Name:
	
 
	
Debanjan Ray

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Title:
	
 
	
Vice President
	
 
	
Title:
	
 
	
SVP Corporate Development

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Date:
	
 
	
February 12, 2016
	
 
	
Date:
	
 
	
February 12, 2016

 

3

[***] Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.ctmx-ex106_180.htm

Confidential Treatment Requested by CytomX Therapeutics, Inc.

 

Exhibit 10.6

THIRD AMENDMENT TO RESEARCH COLLABORATION AGREEMENT

This Third Amendment to Research Collaboration Agreement (the “Third Amendment”) is made effective as of the date of the last signature below by and between ImmunoGen, Inc., a Massachusetts corporation (“lmmunoGen”), with its principal place of business being 830 Winter Street, Waltham, Massachusetts 02451-1477, and CytomX Therapeutics, Inc., a Delaware corporation (“CytomX”), with its principal place of business being 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080. ImmunoGen and CytomX are herein sometimes referred to as a “Party” and collectively as the “Parties.”

WHEREAS, ImmunoGen and CytomX are parties to that certain Research Collaboration Agreement dated as of January 8, 2014, as amended effective April 3, 2015 and February 12, 2016 and (the “RCA”); and 

WHEREAS, the Parties desire to amend the RCA to extend the term of the Research Program with respect to the [***], as set forth in this Third Amendment; and 

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree and covenant as follows.

1.Exercise of ImmunoGen Option. Section 3.1.2 of the RCA is amended by adding the following at the end thereof:

“Anything contained in this Agreement to the contrary notwithstanding, the lmmunoGen Option may be exercised by lmmunoGen with respect to the [***] at any time during the Term, but in no case later than [***]

2.Miscellaneous. Capitalized terms used and not otherwise defined herein shall have the respective meanings ascribed to them in the RCA. The RCA remains in full force and effect, as amended by this Third Amendment. References in the RCA to “Agreement” mean the RCA as amended by this Third Amendment.

[The remainder of this page has been intentionally left blank. The signature page follows.}

[***] Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by CytomX Therapeutics, Inc.

 

IN WITNESS WHEREOF, the Parties have caused this Third Amendment to Research Collaboration Agreement to be executed by their duly authorized representatives.

 

							
	
IMMUNOGEN, INC.
	
 
	
CYTOMX THERAPEUTICS, INC.

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
By:
	
 
	
/s/ Peter Williams
	
 
	
By:
	
 
	
/s/ Cynthia Ladd

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Name:
	
 
	
Peter Williams
	
 
	
Name:
	
 
	
Cynthia Ladd

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Title:
	
 
	
Vice President
	
 
	
Title:
	
 
	
SVP, General Counsel

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Date:
	
 
	
March 3, 2017
	
 
	
Date:
	
 
	
March 3, 2017

 

2

[***] Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.Exhibit

Exhibit 10.1

Termination and Release Agreement
to the
Commercial Supply Contract

between
 
Prothena Biosciences Limited (formerly Prothena Therapeutics Limited)
Adelphi Plaza
Upper George's Street
Dún Laoghaire
Co. Dublin
A96 T927
Ireland 

  (“Customer“)

and

Rentschler Biopharma SE
Erwin-Rentschler-Straße 21,
88471 Laupheim,
Germany

(“Rentschler“)

 Customer and Rentschler each referred to as a “Party” and collectively as the “Parties”.

WHEREAS, Rentschler and Customer entered into a Commercial Supply Contract, effective November 9, 2016, relating to the commercial supply of Product (the “CSC”). 

WHEREAS, Customer has decided to discontinue the development of the Product.

WHEREAS, Customer and Rentschler wish to document the Parties’ agreement with respect to early termination of the CSC.
 
    
NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties agree as follows: 

		
	1.
	The capitalized terms used in this Termination and Release Agreement shall have the meaning as defined herein or, as applicable, the same meaning as defined in the CSC. 

		
	2.
	Notwithstanding any of the terms and conditions of the CSC, Prothena hereby agrees to pay EURO 4,100,000 (four point one million EURO; the “Termination Fee”) in full and final settlement of any and all remaining payments owed by Prothena under the CSC, including without limitation, any and all Exit Fees.  Rentschler shall submit an invoice for such Termination Fee to Prothena, and Prothena shall pay such Termination Fee within 15 days after receipt of such invoice.   

		
	3.
	Notwithstanding any of the terms and condition of the CSC, upon Rentscher’s receipt of the Termination Fee,

		
	a.
	the CSC shall be deemed terminated; and

		
	b.
	Rentschler hereby releases and discharges Prothena from any and all claims, causes of action, demands, damages, liabilities or expenses under the CSC, including without limitation, any and all Exit Fees.

		
	4.
	The provisions of Section 16 (Documents), 17 (Confidentiality) (for the period set forth therein), and 24-32 shall survive termination of the CSC. 

		
	5.
	This Termination and Release Agreement shall be effective shall mean the date on which the Agreement is executed by the duly authorized representatives of each of the Parties hereto. If the Agreement is not executed by all Parties on the same date, the last date of execution shall be the effective date (the “Termination and Release Agreement Effective Date”). 

Signature page follows.

Remainder of this page intentionally left blank.

 2 / 3

		
	6.
	Signature page

IN WITNESS WHEREOF, the Parties have executed this Termination and Release Agreement as of the date below.

	
			
	Rentschler Biopharma SE

Date:             19/7/18

Signature:     /s/ Frank Mathias

Name:           Dr. Frank Mathias

Position:        CEO, Rentschler Biopharma SE

	 
	Rentschler Biopharma SE

Date:             19.07.2018

Signature:     /s/ Stefan Rampf

Name:           Stefan Rampf                            

Position:        CFO, Rentschler Biopharma SE

	Prothena Biosciences Limited

Date:             July 20, 2018                

Signature:     /s/ Yvonne Tchrakian

Name:           Yvonne Tchrakian

Position:        Director
	 
	If second signature is required:

Date:             _________________________

Signature:     _________________________
   
Name:           _________________________

Position:        _________________________

 3 / 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}]]